Apricot Capital describes its mission as connecting China's biotech ecosystem to the global healthcare landscape, pointing to more than 20 licensing deals with companies like Johnson & Johnson, AstraZeneca, BioNTech, Roche, and Novartis worth a combined $45 billion, and it backs this with a team of 20+ investment professionals from clinical, pharmaceutical, and healthcare operations backgrounds, over 300 advisors, and senior leaders like former top-ranked healthcare analyst Arthur Qiang and hospital-management veteran William Mao. Founder Crystal Liu has raised six funds, led investments in nearly 70 life science ventures, holds a doctorate in public health from Johns Hopkins, and has published close to 20 research papers along with a 2024 book on hospital management, while the firm has occasionally invested outside pure healthcare, such as backing Singapore's Geniebook.